NEWS & MEDIA

Beta Capital backs HeartGenetics’ strategy in cardiovascular molecular diagnostics

Beta Capital backs HeartGenetics’ strategy in cardiovascular molecular diagnostics
HeartGenetics is happy to announce that we have raised a new financing round with Beta Capital. Beta Capital is a privately held venture capital firm, which invests in innovative, technology-driven companies.
 
HeartGenetics will use these new financing to growth its products in genetic molecular diagnostics and expand to new international markets. With this capital we will continue to advance HeartGenetics and make improvements to help serve our customers better.
 
Learn more about HeartGenetics products and services here and here
Learn more about Beta Capital here
 
4-1-16 
< Back to News Page
Share this article